The Board of Directors in Xbrane Biopharma AB (publ) has resolved on a capital raise through two new share issues up to a maximum of approximately SEK 238 million. The proceeds from the share issues will primarily be used to finance the ongoing phase III trial with Xlucane.
The share issues require approval from the extra general meeting to be held on 18 June 2019.
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars.
Vator Securities is financial adviser and Baker McKenzie is legal adviser to Xbrane in connection with the capital raise. Baker McKenzie’s team consists of Joakim Falkner, Ian Gulam, Johanna Flink and Olof Larsson.